What smart money is saying about Day One Biopharmaceuticals, Inc.
DAWN
No fund has written a full thesis on Day One Biopharmaceuticals, Inc. in our archive, but 1 fund letter reports a position in it, most recently Timesquare US Small Cap Growth in March 2025.
Get an email when a fund buys, sells or pitches it
1
Reported positions
0
Bought
1
Sold
1
Letter
Position history
Every position in Day One Biopharmaceuticals, Inc. on record in the archive was reported in Q1 2025, across 1 fund letter, with 1 sell (trimmed or exited).
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q1 2025 | 1 | 0 | 1 | 0 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 1 position · 1 move
- March 2025
“Day One Biopharmaceuticals Inc. develops and commercializes targeted therapies for patients with genetically defined cancers. Their lead drug Ojemda is used to treat certain types of brain tumors (gliomas) in patients six months and older. The launch has been promising with 280 patients on therapy in December. Despite its early success, there are concerns about the addressable market and prescribing patterns. We decided to sell out of the position, which declined by -35% for the time it was held in the quarter.”
Day One Biopharmaceuticals, Inc.
Read the letters behind these Day One Biopharmaceuticals, Inc. positions
Every quote above comes from a fund letter in our archive. Get unlimited access to the letters themselves, and to Warren AI, which reads all of them for you.
View plans→Share this ledger